Patents matching “formulation”

US 9687527

Stable glucagon formulations for the treatment of hypoglycemia

The Regents of the University of Colorado, a Body Corporate · Granted Jun 27, 2017 · Expires Jun 22, 2037

US 9682033

Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jun 20, 2017 · Expires Jun 15, 2037

US 9682145

Stable aqueous formulations of adalimumab

Coherus BioSciences, Inc. · Granted Jun 20, 2017 · Expires Jun 15, 2037

US 9675692

Stabilized formulations containing anti-DLL4 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Jun 13, 2017 · Expires Jun 8, 2037

US 9675639

Peroxide formulations and methods and applicators for using the same

Aclaris Therapeutics, Inc. · Granted Jun 13, 2017 · Expires Jun 8, 2037

US 9669076

Albumin-free factor VIII formulations

UNIVERSITY OF CONNECTICUT · Granted Jun 6, 2017 · Expires Jun 1, 2037

US 9662396

Stable aqueous formulations of etanercept

Coherus BioSciences, Inc. · Granted May 30, 2017 · Expires May 25, 2037

US 9662338

Formulations of viloxazine

Supernus Pharmaceuticals, Inc. · Granted May 30, 2017 · Expires May 25, 2037

US 9648899

Drinking water formulation and method and article relating to same

ESSENTIALIFE HOMEOPATHICS · Granted May 16, 2017 · Expires May 11, 2037

US 9649364

Methods for producing stable therapeutic formulations in aprotic polar solvents

XERIS PHARMACEUTICALS, INC. · Granted May 16, 2017 · Expires May 11, 2037

US 9636408

Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

TONIX PHARMA LIMITED · Granted May 2, 2017 · Expires Apr 27, 2037

US 9636400

VEGF specific fusion protein antagonist formulations

REGENERON PHARMACEUTICALS, INC. · Granted May 2, 2017 · Expires Apr 27, 2037

US 9629932

Photodynamic diagnosis, formulations usable as photosensitizers for this purpose, method for the production and use thereof

SANOCHEMIA PHARMAZEUTIKA AG · Granted Apr 25, 2017 · Expires Apr 20, 2037

US 9622983

Sustained-release formulations of topiramate

Supernus Pharmaceuticals, Inc. · Granted Apr 18, 2017 · Expires Apr 13, 2037

US 9623088

Factor VIII polypeptide formulations

BIOVERATIV THERAPEUTICS INC. · Granted Apr 18, 2017 · Expires Apr 13, 2037

US 9616015

Formulations of human tissue kallikrein-1 for parenteral delivery and related methods

DiaMedica Inc. · Granted Apr 11, 2017 · Expires Apr 6, 2037

US 9610352

Lyophilized viral formulations

ONCOLYTICS BIOTECH INC. · Granted Apr 4, 2017 · Expires Mar 30, 2037

US 9610309

Liquid viral formulations

ONCOLYTICS BIOTECH INC. · Granted Apr 4, 2017 · Expires Mar 30, 2037

US 9603907

Dry powder formulations of dNase I

Protalix Ltd. · Granted Mar 28, 2017 · Expires Mar 23, 2037

US 9603906

Inhalable liquid formulations of DNase I

Protalix Ltd. · Granted Mar 28, 2017 · Expires Mar 23, 2037

US 9603853

Formulations of viloxazine

Supernus Pharmaceuticals, Inc. · Granted Mar 28, 2017 · Expires Mar 23, 2037

US 9597353

Redox signaling gel formulation

Reoxcyn Discoveries Group, Inc. · Granted Mar 21, 2017 · Expires Mar 16, 2037

US 9585941

Eye drop formulation

REGENERX BIOPHARMACEUTICALS, INC. · Granted Mar 7, 2017 · Expires Mar 2, 2037

US 9580489

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Feb 28, 2017 · Expires Feb 23, 2037